OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Changes in Registrant’s Certifying AccountantItem4.01Changes in Registrant’s Certifying Accountant.
(a) On April 9, 2018, the Audit Committee of the Board of Directors of Oxford Immunotec Global PLC, or the Registrant, accepted the resignation of Ernst & Young LLP (registered in the U.K.), or EY UK, as the independent registered public accounting firm of the Registrant effective immediately. The Registrant felt it appropriate to request the resignation and change from EY UK, the United Kingdom member firm of Ernst & Young Global Limited that has traditionally serviced the Registrant, to Ernst & Young Global Limited’s U.S. member firm, Ernst & Young LLP (registered in the U.S.), or EY US, to facilitate the logistics of the Registrant’s quarterly reviews and annual audits. The Registrant will continue to use EY UK, as its statutory auditor for filings with Companies House in the United Kingdom.
The reports of EY UK on the Registrant’s consolidated financial statements for the fiscal years ended December 31, 2017 and 2016 did not contain an adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles.
In connection with the audits of the Registrant’s financial statements for each of the two fiscal years in the period ended December 31, 2017, and the subsequent period through April 12, 2018, there were (i) no disagreements with EY UK on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of EY UK, would have caused EY UK to make reference to the matter in their reports on the Registrant’s consolidated financial statements for such periods, and (ii) no reportable events as set forth in Item 304(a)(1)(v) of Regulation S-K.
The Registrant provided EY UK with a copy of this Current Report on Form 8-K and requested from EY UK a letter addressed to the U.S. Securities and Exchange Commission indicating whether or not it agrees with the above disclosures. A copy of the EY UK letter dated April 12, 2018 is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) On April 9, 2018, the Audit Committee of the Board of Directors of the Registrant approved the engagement of EY US as its independent registered public accounting firm for the fiscal year ending December 31, 2018, effective immediately.
During the Registrant’s two most recent fiscal years and through the date of its engagement of EY US, neither the Registrant nor anyone on its behalf consulted with EY US regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to its financial statements, and no written report or oral advice was provided to the Registrant by EY US that was an important factor considered by the Registrant in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Act of 1933, as amended, and the related instructions) or a reportable event (as that term is defined in Item 304(a)(1)(v) of Regulation S-K) relating to the Registrant.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Oxford Immunotec Global PLC ExhibitEX-16.1 2 ex_110185.htm EXHIBIT 16.1 ex_110185.htm Exhibit 16.1 Securities and Exchange Commission 100 F Street,…To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.